Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06663722 · ClinicalTrials.gov registry record · Phase 2
Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease
A Phase 2 study of Chronic Graft Versus Host Disease and cGVHD, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT06663722: Recruiting Phase 2 study of Chronic Graft Versus Host Disease and cGVHD, sponsored by University of Miami.
NCT06663722 is a Phase 2 study of Chronic Graft Versus Host Disease and cGVHD that is actively recruiting participants, run by University of Miami. The registered enrollment target is 49 participants, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (57% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06663722, a Phase 2 study of Chronic Graft Versus Host Disease and cGVHD, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).
Primary Outcome
Best overall response rate (ORR) will be reported as the percentage of participants who achieve partial response (PR) or a complete response (CR) to study therapy, as defined by the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical Trials in chronic graft-versus-host disease (cGVHD) while on study treatment.
Conditions Studied
Interventions
- BIOLOGICAL Axatilimab
- PROCEDURE Extracorporeal Photopheresis
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2025-05-05 |
| Est. Completion | 2030-05-05 |
| Phase | Phase 2 |
What NCT06663722 shows while recruiting
NCT06663722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 115-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (57% lower).
The record links to 2 conditions, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 2 interventions - of which Axatilimab is the first listed.
NCT06663722 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT06663722 about?
NCT06663722 is a clinical study titled "Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease". The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).
What is the current status of trial NCT06663722?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2025-05-05. Estimated completion is 2030-05-05.
What conditions does trial NCT06663722 study?
This clinical trial studies the following conditions: Chronic Graft Versus Host Disease, cGVHD.
What interventions are being tested in trial NCT06663722?
The interventions under investigation include: Axatilimab (BIOLOGICAL), Extracorporeal Photopheresis (PROCEDURE).
Who is sponsoring clinical trial NCT06663722?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06663722 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Graft Versus Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06663722's enrollment target sits among peer trials
49 13th of 30 higher than 18 of 30 other Chronic Graft Versus Host Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Graft Versus Host Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP)
RECRUITING · Phase 2
-
Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease
RECRUITING · Phase 2
-
Axatilimab for Sclerotic Chronic Graft-versus-Host Disease
RECRUITING · Phase 2
-
Belumosudil and Rituximab for Primary Treatment of Chronic Graft-Versus-Host-Disease
RECRUITING · Phase 2
-
A Study of Belumosudil in Children With Chronic Graft Versus Host Disease (schoolROCK)
RECRUITING · Phase 2
-
Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI